| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
5
5
5
1
|
|
Zacks Investment Research
3
(Hold)
|
|
Standard & Poor's
5 / 5 Stars
|
|
TheStreet.com
A+
(Buy)
|
#24 in Large Value
U.S. News evaluated 328 Large Value Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
Performance
The fund has returned 29.76 percent over the past year, 20.04 percent over the past three years, 7.10 percent over the past five years, and 7.47 percent over the past decade.
| Trailing Returns | Updated 05.31.2013 |
|---|---|
| Year to date | 17.9% |
| 1 Year | 29.8% |
| 3 Years (Annualized) | 20.0% |
| 5 Years (Annualized) | 7.1% |
| 10 Years (Annualized) | 7.5% |
Summary
GMO U.S. Intrinsic Value has been having a good year.
As of June 05, 2013, the fund has assets totaling almost $11.73 million invested in 166 different holdings. Its portfolio consists primarily of shares of large companies.
Lately, this fund has been on a roll. As of the end of May, its year-to-date returns were 4 percentage points better than those of the broader market. That's largely thanks to the fund's outsized stake in healthcare companies. As of late 2010, that sector represented a quarter of its stock holdings. So far in 2011, healthcare companies such as Pfizer and UnitedHealth Group have added juice to the fund's results. Meanwhile, Microsoft has been a significant detractor. The fund has returned 29.76 percent over the past year and 20.04 percent over the past three years.
Historically, this fund has hardly been immune to poor performance. Notably, the fund finished both 2006 and 2007 in the bottom 20 percent of its Morningstar category. Those results are still reflected in the fund's long-term numbers. Nonetheless, the fund is, in many senses, a cautious pick. While it is somewhat concentrated by sector, it makes up for that by spreading its assets among a large number of companies. This diversification helps make the ride a smoother one. The fund has returned 7.10 percent over the past five years and 7.47 percent over the past decade.
Investment Strategy
According to the fund's prospectus: "The Manager selects equity investments it believes (i) are undervalued (e.g., equity investments trading at prices below what the Manager believes to be their fundamental value); (ii) have superior fundamentals (e.g., earnings stability); and/or (iii) have shown indications of improving investor sentiment (e.g., positive price movement or upgraded analyst ratings)."
Role in Portfolio
The fund can lend support to a well-balanced portfolio.
Management
Sam Wilderman and Thomas Hancock manage the fund.
